NHI to reimburse additional indication of Aricept.

The NHI reimbursement for Aricept, an Eisai Korea drug in an additional indication of vascular schizophrenia to Alzheimer disease has been approved according to the revised ordinance dated on Jan. 31 titled "Standards for NHI payment and its detailed particulars for the methods"

According to the ordinance, the NHI reimbursement coverage of Aricept (donepezil) include a light and moderate de...